COVID-19相关呼吸窘迫中应用组织型纤溶酶原激活剂的早期结局:五例病例系列
本文为五例COVID-19阳性、严重低氧血症(PaO2≤80)且D-二聚体>1.5 μg/mL、传统支持措施下呼吸功能仍恶化的患者病例系列,均接受方案指导的组织型纤溶酶原激活剂(tPA)溶栓治疗。一例机械通气患者PaO2/FIO2比值从69升至127,治疗后第1天开始撤机、第12天拔管;其余四例未插管者中三例避免插管。全部患者氧合改善且无溶栓不良效应。作者认为溶栓治疗可能改善氧需求并阻止机械通气进展,建议开展临床试验进一步验证。
要点
- 纳入标准:COVID-19阳性、呼吸功能恶化、传统支持措施下仍严重低氧血症(PaO2≤80)、氧需求升级、D-二聚体>1.5 μg/mL。
- 五例均接受方案指导的tPA溶栓,全部氧合改善且无溶栓不良效应。
- 例1机械通气最大值+肌松+俯卧位无改善,tPA后PaO2/FIO2由69升至127,第1天开始撤机、第12天拔管。
- 例2至例5在tPA启动时未插管,均需显著氧疗且趋向插管,tPA后PaO2随时间明显升高,其中三例避免插管。
适用人群与场景
- COVID-19阳性、呼吸功能恶化、传统支持措施下仍严重低氧血症(PaO2≤80)、氧需求升级且D-二聚体>1.5 μg/mL的患者。
- 五例中一例在tPA启动时接受最大呼吸机支持、肌松剂和俯卧位通气,其余四例未插管但需显著氧疗且趋向插管。
诊断标准与关键阈值
- 纳入条件:COVID-19阳性、呼吸功能恶化、传统支持措施下严重低氧血症(PaO2≤80)、氧需求升级、D-二聚体>1.5 μg/mL。
处置流程与药物剂量
- 全部患者接受方案指导的溶栓治疗,药物为组织型纤溶酶原激活剂(tPA)。
研究设计与关键结果
- 五例病例系列:全部患者接受tPA后氧合改善,无溶栓治疗不良效应。
- 例1(tPA启动时最大呼吸机支持、肌松剂、俯卧位无改善):tPA期间PaO2/FIO2比值由69升至127,治疗后第1天立即开始撤机,第12天拔管。
- 例2至例5(tPA启动时未插管、需显著氧疗且趋向插管):tPA后全部患者PaO2随时间明显升高;其中三例因COVID-19相关呼吸衰竭避免插管。
证据类型、等级与局限
- 证据类型:病例系列(治疗效应),证据等级Level V。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,溶栓治疗与患者氧需求整体改善相关,并在三例中阻止了向机械通气的进展,且无不良效应。
- 作者认为,溶栓治疗的临床试验将进一步验证该疗法的疗效和实用性。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Coronavirus patients demonstrate varying degrees of respiratory insufficiency; many will progress to respiratory failure with a severe version of acute respiratory distress syndrome refractory to traditional supportive strategies. Providers must consider alternative therapies to deter or prevent the cascade of decompensation to fulminant respiratory failure.
METHODS: This is a case-series of five COVID-19 positive patients who demonstrated severe hypoxemia, declining respiratory performance, and escalating oxygen requirements. Patients met the following criteria: COVID-19 positivity, worsening respiratory performance, severe hypoxemia (PaO2 ≤ 80) despite traditional supportive measures, escalating supplemental oxygen requirements, and D-dimer greater than 1.5 μg/mL. All patients received protocol directed thrombolytic therapy with tissue plasminogen activator (tPA).
RESULTS: All five patients improved without deleterious effects of thrombolytic therapy. Patient one was on maximum ventilator support, paralytics, and prone positioning without improvement. During tPA administration his PaO2/FIO2 ratio improved from 69 to 127. Ventilator support was weaned immediately on posttreatment day 1, and he was extubated on posttreatment day 12. Our second through fifth patients were not intubated at time of initiation of tPA therapy. These patients each required significant oxygen supplementation trending toward intubation. After tPA therapy, all patients demonstrated a noticeable increase in PaO2 values overtime. Three of these patients avoided intubation due to COVID-19-associated respiratory failure.
CONCLUSION: Administration of thrombolytics was followed by overall improvement in patients' oxygen requirements, and in three cases, prevented progression to mechanical ventilation, without deleterious effects. Clinical trials of thrombolytic therapy would further serve to underscore the efficacy and utility of this therapy.
LEVEL OF EVIDENCE: Case series of therapeutic effect, Level V.
参考来源
- Christie DB, Nemec HM, Scott AM, et al. Early outcomes with utilization of tissue plasminogen activator in COVID-19-associated respiratory distress: A series of five cases. J Trauma Acute Care Surg. 2020. PMID: 32427774. doi:10.1097/TA.0000000000002787
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。